STOCK TITAN

Tango Therapeutics director sells 3,333 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Tango Therapeutics, Inc. director John B. Ketchum sold 3,333 shares of common stock on November 17, 2026, at a weighted-average sale price of $24.08 per share; individual sale prices ranged from $24.08 to $25.0799. The sale was made under a Rule 10b5-1 trading plan adopted August 18, 2026. Shares reported following the sale totaled 21,604, including 4,000 unvested RSUs.

Insider Ketchum John B
Role Director
Sold 3,333 shs ($80K)
Share of Position Sold 13.4%
Type Security Shares Price Value
Sale Common Stock F1, F2, F3 3,333 $24.08 $80K
Holdings After Transaction: Common Stock — 21,604 shares (Direct)
Holdings Before and After: Common Stock, 24,937 to 21,604 shares (Direct)
Other Insiders: 2 other insiders reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (3)
  1. F1. The transaction was effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 18, 2026.
  2. F2. Represents the weighted average sales price per share. The shares sold at prices ranging from $24.08 to $25.0799 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  3. F3. The amount reported in Column 5 includes Restricted Stock Units ("RSUs"), including 4,000 unvested RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.
Shares sold 3,333 shares November 17, 2026
Weighted-average sale price $24.08 per share Sale prices ranged from $24.08 to $25.0799 per share
Reported shares following transaction 21,604 shares Includes 4,000 unvested RSUs
Unvested RSUs 4,000 RSUs Included in the amount reported following the sale
Rule 10b5-1 trading plan regulatory
"the transaction was effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Restricted Stock Units (RSUs) financial
"the amount reported includes 4,000 unvested RSUs"
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did TNGX director John B. Ketchum sell, and at what price?

He sold 3,333 shares at a weighted average of $24.08 per share, with individual sale prices ranging from $24.08 to $25.0799. The sale was made under a Rule 10b5-1 trading plan adopted on August 18, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ketchum John B

(Last)(First)(Middle)
C/O TANGO THERAPEUTICS, INC.
201 BROOKLINE AVE., SUITE 901

(Street)
BOSTON MASSACHUSETTS 02215

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Tango Therapeutics, Inc. [ TNGX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/17/2026S(1)3,333D$24.08(2)21,604(3)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The transaction was effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 18, 2026.
2. Represents the weighted average sales price per share. The shares sold at prices ranging from $24.08 to $25.0799 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
3. The amount reported in Column 5 includes Restricted Stock Units ("RSUs"), including 4,000 unvested RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.
/s/ Julie Fogarty, as attorney-in-fact11/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading